{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"The null hypothesis is that there is no significant difference in Aurora kinase A expression between responders and non-responders.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2316","statisticalComment":"Two-sided alpha level of 0.05","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.096","value":"0.121"},{"groupId":"OG001","spread":"0.060","value":"0.063"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"To explore the association between pre-treatment aurora kinase A expression in tumor biopsies as measured by fluorescence in situ hybridization (FISH) and objective response rate in patients with PTCL treated with MLN8237","dispersionType":"Standard Deviation","groups":[{"description":"Eligible patients who received protocol treatment and did not respond to the protocol treatment. Patients for whom response assessment was inadequate were considered non-responders.","id":"OG000","title":"Non-responders"},{"description":"Eligible Patients who received protocol treatment and achieved complete or partial response.","id":"OG001","title":"Responders"}],"paramType":"MEAN","populationDescription":"Eligible patients who consented for correlative studies and had Aurora kinase A expression measured.","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Aurora Kinase A Expression","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"proportion of positivity"}